BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) stock jumped 0.73% on Monday to $2.77 against a previous-day closing price of $2.75. With 0.71 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.13 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.0000 whereas the lowest price it dropped to was $2.6600. The 52-week range on BVXV shows that it touched its highest point at $22.90 and its lowest point at $2.37 during that stretch. It currently has a 1-year price target of $63.50. Beta for the stock currently stands at 2.57.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BVXV was down-trending over the past week, with a drop of -1.77%, but this was down by -15.03% over a month. Three-month performance dropped to -56.38% while six-month performance fell -77.30%. The stock lost -82.47% in the past year, while it has lost -6.42% so far this year. A look at the trailing 12-month EPS for BVXV yields -5.55 with Next year EPS estimates of -0.20. For the next quarter, that number is -0.10. This implies an EPS growth rate of -604.60% for this year and -566.70% for next year.
Float and Shares Shorts:
At present, 1.87 million BVXV shares are outstanding with a float of 1.36 million shares on hand for trading. On Oct 13, 2022, short shares totaled 0.14 million, which was 0.76% higher than short shares on Sep 14, 2022. In addition to Mr. Amir Reichman M.B.A., M.Sc. as the firm’s CEO & Director, Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA serves as its Chief Financial Officer.
Through their ownership of 1.80% of BVXV’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 12.28% of BVXV, in contrast to 0.94% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in BVXV with 12.11% of the stake, Sabby Management LLC holds 228,329 shares worth 228,329. A second-largest stockholder of BVXV, Envestnet Asset Management, Inc., holds 7,922 shares, controlling over 0.42% of the firm’s shares. True Private Wealth Advisors LLC is the third largest shareholder in BVXV, holding 4,700 shares or 0.25% stake. With a 0.87% stake in BVXV, the Trust for Professional Managers – is the largest stakeholder. A total of 16,342 shares are owned by the mutual fund manager. The Fidelity Nasdaq Composite Index F, which owns about 0.07% of BVXV stock, is the second-largest Mutual Fund holder. It holds 1,376 shares valued at 4073.0. SPDR Portfolio Developed World ex holds 0.00% of the stake in BVXV, owning 29 shares worth 86.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BVXV since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BVXV analysts setting a high price target of $70.00 and a low target of $57.00, the average target price over the next 12 months is $63.50. Based on these targets, BVXV could surge 2427.08% to reach the target high and rise by 1957.76% to reach the target low. Reaching the average price target will result in a growth of 2192.42% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. BVXV will report FY 2022 earnings on 03/25/2024. Analysts have provided yearly estimates in a range of -$0.30 being high and -$5.62 being low. For BVXV, this leads to a yearly average estimate of -$2.96. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. BiondVax Pharmaceuticals Ltd. surprised analysts by $0.10 when it reported $0.00 EPS against a consensus estimate of -$0.10. The surprise factor in the prior quarter was $0.04. Based on analyst estimates, the high estimate for the next quarter is -$0.10 and the low estimate is -$1.08. The average estimate for the next quarter is thus -$0.59.